Sep 24th, 2018 - A new oral drug for use in patients with certain blood cancers has been approved by the US Food and Drug Administration (FDA). The drug, duvelisib (Copiktra, Verstem Oncology), is an oral inhibitor of phosphoinositide 3–kinase (PI3K) and is the first to act as a dual inhibitor of PI3K-delta and PI3K-gamma. The FDA granted approval for use of duvelisib in adult patients with relapsed or refracto...

Sep 24th, 2018 - A new oral drug for use in patients with certain blood cancers has been approved by the US Food and Drug Administration (FDA). The drug, duvelisib (Copiktra, Verstem Oncology), is an oral inhibitor of phosphoinositide 3–kinase (PI3K) and is the first to act as a dual inhibitor of PI3K-delta and PI3K-gamma. The FDA granted approval for use of duvelisib in adult patients with relapsed or refracto...

Mar 6th, 2018 - The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the United States for the treatm...

Mar 6th, 2018 - The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the United States for the treatm...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the United States for the treatm...

A new oral drug for use in patients with certain blood cancers has been approved by the US Food and Drug Administration (FDA). The drug, duvelisib (Copiktra, Verstem Oncology), is an oral inhibitor of phosphoinositide 3–kinase (PI3K) and is the first to act as a dual inhibitor of PI3K-delta and PI3K-gamma. The FDA granted approval for use of duvelisib in adult patients with relapsed or refracto...